Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial Results

– Company ended the year with $50.6 million in cash, expected to fund operations through 2024 and into 2025
– Executing strategy to streamline advancement of development programs, build upon growing body of data across pipeline, and progress towards go/no-go decision milestones
– Ongoing efforts to accelerate recruitment for our DETECT trial and establish partnering rights to Macrilen^™ in the U.S. and Canada

Read more at globenewswire.com